MedTrace Logo

Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty

NCT00485693 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2022-06-28

Study results available
· View outcomes & findings →

Summary

Dose-ranging study for prolonged postoperative analgesia in subjects undergoing total knee arthroplasty

Conditions

  • Postoperative Pain

Interventions

DRUG

Bupivacaine HCl

150 mg Bupivacaine HCl

DRUG

SKY0402

600 mg SKY0402 (study drug)

Sponsors & Collaborators

  • Pacira Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Joyce Davis, RN · Pacira Pharmaceuticals, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States
  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00485693 on ClinicalTrials.gov